Benítez-Arvizu G, Franco-Gómez NE, Flores-Sánchez I, Ojeda JJ, Moreno-Alcantar R

Language: Spanish
References: 8
Page: 18-21
PDF size: 170.05 Kb.

ABSTRACT

Currently with the development of molecular biology techniques it is possible to detect evidence infections through the genome of the agent even before it can be evidenced by serological tests, this has reduced the window period in the detection of infections in consequence increasing transfusion safety avoid transfusion transmissible diseases. In this paper we exposed the detection of one window period for hepatitis B, showing the infection by nucleic acid technology (NAT) before to seroconversion, which is documented trough blood donor following. The implementation of this technology in the blood banks has increased transfusion safety and decreased the risk of transmission of infections across transfusion.

REFERENCES

1. Universal Access to Safe Blood Transfusion © World Health Organization 2008. Switzerland.

2. Rojo MJ. Enfermedades infecciosas transmitidas por transfusión. Panorama internacional y en México. Gac Med Mex. 2014; 150: 78-83.

3. Fishman JA, Grossi PA. Donor derived infection-the challenge for transplant safety. Nat Rev Nephrol. 2014; 10 (11): 663-672.

4. Novelo-Garza B, Benitez-Arvizu G, Galvan-Cervantes J, Morales-Rojas A. Vox Sanguinis. 2012; 103 (Suppl. 1): 154.

5. Norma Oficial Mexicana NOM-SSA1-253-2012 para la disposición de sangre humana y sus componentes con fines terapéuticos.

6. Vermeulen M, Van Drimmelen H, Coleman C, Mitchel J, Reddy R, Lelie N. A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections. Transfusion. 2014; 54 (10): 2496-2504.

7. Novelo-Garza B, Benítez-Arvizu G. A 30 años de la epidemia del VIH transfusional: reflexiones sobre la seguridad sanguínea en México. Rev Mex Med Tran. 2014; 7 (1): 45-50.

8. Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res. 2011; 3: 37-46.